20:40 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

India set to approve Biocad's biosimilar rituximab

Biocad CJSC (Saint Petersburg, Russia) said India’s Central Drugs Standard Control Organization (CDSCO) recommended approval of AcellBia (BCD-020), a biosimilar of rituximab. Biocad expects the product be approved next month, with a launch planned for...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

BCD-085: Phase II started

Biocad began a double-blind, placebo-controlled, international Phase II trial to evaluate 40, 80 and 120 mg subcutaneous BCD-085 at weeks 0, 1, 2, 4, 6, 8 and 10 in about 120 patients. Biocad CJSC ,...
07:00 , Jul 25, 2016 |  BioCentury  |  Strategy

Paving the way

Amgen Inc. and the Sandoz unit of Novartis AG are charting a course that could create competitive U.S. markets for two of the biggest prizes in the biosimilars universe, AbbVie Inc .'s Humira adalimumab and...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Bevacizumab biosimilar regulatory update

Biocad said Russia approved the company’s biosimilar of cancer drug Avastin bevacizumab. Biocad plans to launch the biosimilar next quarter and said it will be priced 30% less than the price of Avastin from Roche...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Biocad, Millhouse, Pharmstandard deal

Pharmstandard and Russian investment firm Millhouse completed the acquisition of a combined 70% stake in Russian biosimilar play Biocad. Pharmstandard acquired a 20% stake and Millhouse acquired a 50% stake. Biocad founder and CEO Dmitri...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Biocad, Pharmstandard, Millhouse LLC deal

Pharmstandard and Russian investment firm Millhouse are acquiring a combined 70% stake in Russian biosimilar play Biocad. Pharmstandard will acquire a 20% stake, while Millhouse will acquire a 50% stake. Biocad founder and CEO Dmitri...
00:30 , May 24, 2014 |  BC Extra  |  Company News

Pharmstandard, Millhouse to gain stake in Russian biosimilar play

Pharmstandard OJSC (RTS:PHST; LSE:PHST) and Russian investment firm Millhouse LLC are acquiring a combined 70% stake in Russian biosimilar company Biocad CJSC (St. Petersburg, Russia). Pharmstandard will acquire a 20% stake, while Millhouse will acquire...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

AcellBia rituximab regulatory update

Biocad said the Russian Ministry of Health approved the company's AcellBia, a biosimilar of rituximab for autoimmune and cancer indications. Biocad said AcellBia is the first mAb biosimilar to be approved in Russia. The company...
00:03 , Apr 23, 2014 |  BC Extra  |  Company News

Biocad's rituximab biosimilar approved in Russia

Biocad (St. Petersburg, Russia) said the Russian Ministry of Health approved the company's AcellBia (BCD-20), a biosimilar of autoimmune and cancer drug rituximab. Biocad said AcellBia is the first mAb biosimilar to be approved in...
07:00 , Jul 17, 1995 |  BC Week In Review  |  Company News

PerSeptive sales and marketing update

PBIO introduced the Scout Column Selector, an automated, multi-column switching device for use with PBIO's BioCAD and BioCAD/Sprint Perfusion Chromatography Systems. Scout extends the purification capability of PBIO's perfusion chromatography technology by automating and accelerating...